CC-115

DB12740InvestigationalSmall molecule

CC-115 has been used in trials studying the treatment of Prostate Cancer, Neoplasm Metastasis, Ewing's Osteosarcoma, Glioblastoma Multiforme, and Chronic Lymphocytic Leukemia, among others.

Mechanism: Pharmacologically active on DNA-dependent protein kinase catalytic subunit and Serine/threonine-protein kinase mTOR
Curator reviewed
Formula / weight: C₁₆H₁₆N₈O · 336.359 g/mol (avg)
Code names: CC-115

Resolves to

Compound

UNIIFII75TFH5LCAS1228013-15-7ChEMBLCHEMBL3586573PubChem58298318

Structure

InChIKeyGMYLVKUGJMYTFB-UHFFFAOYSA-NSMILESCCN1C(=O)CNC2=C1N=C(C=N2)C1=CC=C(N=C1C)C1=NN=CN1

Targets

P78527PRKDCP42345MTOR

What you can answer from here — as of September 21, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with CC-115, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account